Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals to $50 from $40 and keeps an Overweight rating on the shares. The firm says Xdemvy’s strong launch continued in the first full quarter with above consensus Q4 sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARS:
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
- Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
